This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Congruence TX


Congruence Therapeutics is building a pre-eminent next-generation drug discovery company by harnessing a distinctive, scalable computational platform, Revenir™, to rapidly and efficiently discover a pipeline of small molecules designed to target and correct the foundations of severe disease. Our groundbreaking discovery engine, Revenir™, uniquely combines and harnesses the power of innovative fields, such as molecular biophysics, protein dynamics, Artificial Intelligence (AI), computational chemistry, and machine learning to reveal allosteric and cryptic pockets on drug targets that are invisible to traditional methodologies. This revolutionary process captures proteins in their dynamic state in order to map features that differ between benign and mutated protein landscapes. Once the best binding pockets have been identified, virtual small molecules are docked and screened against these pockets in order to predict which ones are capable of correcting the biophysical defect responsible for disease. We have demonstrated in numerous examples that small molecule binders can shift the protein conformation landscape back from the pathogenic state to wild-type. These small molecules are then synthesized in tested in our wet labs for their ability to rescue function in these proteins. Revenir™ sees proteins in ways others have been unable to see- in their full dynamic state. This allows us to move away from historically static and inefficient drug discovery processes towards truly predictive models where the pathogenesis of disease can be corrected in silico at unprecedented speed and accuracy.